Islamabad/Lahore, July 30, 2025: The Drug Regulatory Authority of Pakistan (DRAP) and the Punjab Quality Control Directorate have intensified their crackdown on counterfeit and substandard medicines across the country. As part of their ongoing inspections, five more pharmaceutical products have been declared substandard following tests conducted at the Drug Testing Laboratory.
According to an official public notice, the following medicines failed to meet quality standards:
- Tablet AMLOShine (Amlodipine 5mg) — Manufactured by Sunshine Pharmaceuticals, Gujranwala
- Injection Zakty-L 20 (Tyloxin Tartarate) — Manufactured by Zakfas Pharmaceuticals, Lahore
- Powder for Injection Tylan (Tylosin Base) — Produced by MTI Medicare Ltd., Lahore
- Injection Ketamine Hydrochloride — Manufactured by KWALITY Pharmaceuticals, Kasur
- Injection Lincomycin HCL — Produced by Trigon Pharmaceuticals, Faisalabad
A formal notification has been issued regarding the matter. The public has been strictly advised not to use these medicines, while the respective pharmaceutical companies have been instructed to immediately recall the affected batches from the market.
Authorities reaffirmed their commitment to ensuring the availability of safe and effective medicines and warned that further action would be taken against violators under the Drug Act.
